The adverse effects should also be considered because there have been individual cases where the peptides didnt go well with the users
Therefore the role of glucagon in the body is to maintain an adequate supply of glucose even in the fasting state
However, their ability to promote weight loss has led to an expanded use
Endocrinology (2017) 158:104963
Drug exposure The study cohort consisted of new users of GLP-1RAs (dulaglutide, exenatide, liraglutide, lixisenatide or semaglutide), SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin), metformin and other second- or third-line glucose-lowering drugs (thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sulfonylureas, meglitinides, -glucosidase inhibitors, insulin or a combination of glucose-lowering drugs)